Yukuan Feng
Overview
Explore the profile of Yukuan Feng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
547
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhou T, Yan J, Xu B, Zhang Y, Mao G, Xie Y, et al.
Cancer Lett
. 2024 Dec;
611():217408.
PMID: 39710057
Senescent cells are in a stable state of cell cycle arrest, leading to a natural barrier to tumorigenesis. Senescent cells secrete a pool of molecules, including cytokines, chemokines, proteases, and...
2.
Sun H, Li H, Guan Y, Yuan Y, Xu C, Fu D, et al.
Sci Adv
. 2024 Jun;
10(25):eadj8650.
PMID: 38896624
Pancreatic adenocarcinoma is the fourth leading cause of malignancy-related deaths, with rapid development of drug resistance driven by pancreatic cancer stem cells. However, the mechanisms sustaining stemness and chemotherapy resistance...
3.
Wang Y, Hu J, Fleishman J, Li Y, Ren Z, Wang J, et al.
Front Pharmacol
. 2024 Jun;
15:1290183.
PMID: 38855750
Lung cancer is the leading cause of global cancer-related deaths. Platinum-based chemotherapy is the first-line treatment for the most common type of lung cancer, i.e., non-small-cell lung cancer (NSCLC), but...
4.
Sun H, Ge Y, Liu J, Li Z, Li H, Zhao T, et al.
Oncogene
. 2024 Jan;
43(11):776-788.
PMID: 38243080
Rapid development of drug resistance after chemotherapy is a major cause of treatment failure in individuals with pancreatic ductal adenocarcinoma (PDAC). In this study, we illustrate that tumor-derived interleukin 35...
5.
Wang Y, Hu J, Wu S, Fleishman J, Li Y, Xu Y, et al.
Signal Transduct Target Ther
. 2023 Dec;
8(1):449.
PMID: 38072908
Ferroptosis, a unique modality of cell death with mechanistic and morphological differences from other cell death modes, plays a pivotal role in regulating tumorigenesis and offers a new opportunity for...
6.
She C, Wu C, Guo W, Xie Y, Li S, Liu W, et al.
J Exp Clin Cancer Res
. 2023 Sep;
42(1):238.
PMID: 37697370
Background: Gemcitabine (GEM)-based chemotherapy is the first-line option for pancreatic ductal adenocarcinoma (PDAC). However, the development of drug resistance limits its efficacy, and the specific mechanisms remain largely unknown. RUNX1,...
7.
Fu D, Yan J, Zhang Z, Liu Y, Ma X, Ding J, et al.
Cancer Biol Med
. 2023 Jun;
20(8).
PMID: 37381714
Objective: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant gastrointestinal cancer with a 5-year survival rate of only 9%. Of PDAC patients, 15%-20% are eligible for radical surgery. Gemcitabine is...
8.
Jia G, Wang Y, Lin C, Lai S, Dai H, Wang Z, et al.
J Exp Clin Cancer Res
. 2023 Mar;
42(1):54.
PMID: 36864449
No abstract available.
9.
Zhao L, Su H, Liu X, Wang H, Feng Y, Wang Y, et al.
Cell Biosci
. 2022 Nov;
12(1):183.
PMID: 36371321
Background: Exploiting cancer metabolism during nutrient availability holds immense potential for the clinical and therapeutic benefits of hepatocellular carcinoma (HCC) patients. Dietary methionine is a metabolic dependence of cancer development,...
10.
Mei L, Meng J, Wei D, Hu Q, Chen Y, Cui T, et al.
Ann Transl Med
. 2022 May;
10(8):471.
PMID: 35571399
Background: Colposcopy is a critical component of cervical cancer screening services, but the accuracy of colposcopy varies greatly due to the lack of standardized training for colposcopists and pathologists. Thus,...